MA52123A - Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 - Google Patents
Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2Info
- Publication number
- MA52123A MA52123A MA052123A MA52123A MA52123A MA 52123 A MA52123 A MA 52123A MA 052123 A MA052123 A MA 052123A MA 52123 A MA52123 A MA 52123A MA 52123 A MA52123 A MA 52123A
- Authority
- MA
- Morocco
- Prior art keywords
- erk1
- pyrimidine
- inhibitor
- derivative used
- isoindole derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706327.2A GB201706327D0 (en) | 2017-04-20 | 2017-04-20 | A pharmaceutical compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52123A true MA52123A (fr) | 2020-02-26 |
Family
ID=58795788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052123A MA52123A (fr) | 2017-04-20 | 2018-04-20 | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11142518B2 (fr) |
| EP (1) | EP3612524A1 (fr) |
| JP (1) | JP7113846B2 (fr) |
| KR (1) | KR102652193B1 (fr) |
| CN (1) | CN110831939A (fr) |
| AU (1) | AU2018255935B2 (fr) |
| BR (1) | BR112019019948A2 (fr) |
| CA (1) | CA3059674A1 (fr) |
| GB (1) | GB201706327D0 (fr) |
| IL (1) | IL269803B (fr) |
| MA (1) | MA52123A (fr) |
| MX (1) | MX2019012471A (fr) |
| PH (1) | PH12019502154A1 (fr) |
| SA (1) | SA519410253B1 (fr) |
| SG (1) | SG11201909189QA (fr) |
| TW (1) | TWI813566B (fr) |
| WO (1) | WO2018193410A1 (fr) |
| ZA (1) | ZA201907484B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3001799A1 (fr) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Composes benzolactames utilises en tant qu'inhibiteurs de proteine kinase |
| NZ766835A (en) | 2018-03-02 | 2023-09-29 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| TW202140024A (zh) * | 2020-01-24 | 2021-11-01 | 日商大鵬藥品工業股份有限公司 | Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強 |
| IL297743B2 (en) | 2020-04-30 | 2024-06-01 | Medshine Discovery Inc | Compounds containing benzosulatum |
| CN113967198A (zh) * | 2020-07-24 | 2022-01-25 | 鲁南制药集团股份有限公司 | 一种甾体cyp17抑制剂胶囊及其制备方法 |
| KR20230054696A (ko) * | 2020-08-21 | 2023-04-25 | 상하이 린진 바이오파마 씨오., 엘티디. | 방향족 고리 락탐계 화합물, 이의 제조 방법 및 용도 |
| CA3222540A1 (fr) | 2021-06-11 | 2022-12-15 | Otsuka Pharmaceutical Co., Ltd. | Procede de preparation d'un inhibiteur d'erk |
| US11931370B2 (en) * | 2021-10-08 | 2024-03-19 | Slayback Pharma Llc | Stable pharmaceutical compositions of cyclophosphamide |
| CN118119381A (zh) * | 2021-10-26 | 2024-05-31 | 大冢制药株式会社 | 包含erk抑制剂的组合物 |
| CN114085213B (zh) * | 2022-01-20 | 2022-03-25 | 苏州国匡医药科技有限公司 | 一种arv-471的制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| AU3213799A (en) | 1998-04-01 | 1999-10-18 | Du Pont Pharmaceuticals Company | Integrin antagonists |
| EP1397142A4 (fr) | 2001-06-19 | 2004-11-03 | Bristol Myers Squibb Co | Inhibiteurs pyrimidine de la phosphodiesterase (pde) 7 |
| JP2006525357A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | プロテインチロシンホスファターゼ阻害物質としての置換ヘテロアリール類 |
| CA2536954C (fr) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | Modulateurs c-kit et leurs procedes d'utilisation |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| ES2751761T3 (es) | 2004-05-14 | 2020-04-01 | Vertex Pharma | Compuestos de pirrol como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos |
| US20060235036A1 (en) | 2005-04-15 | 2006-10-19 | Doherty Elizabeth M | Vanilloid receptor ligands and their use in treatments |
| DK1966151T3 (da) | 2005-12-13 | 2012-01-30 | Schering Corp | Polycykliske indazolderivater, der er ERK-hæmmere |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008003766A2 (fr) | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | Nouveaux composés |
| WO2008008059A1 (fr) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Agents anti-cancer et leurs utilisations |
| WO2008124085A2 (fr) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Méthodes d'utilisation de combinaisons d'inhibiteurs de mek et de jak-2 |
| WO2009017838A2 (fr) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinaisons d'inhibiteurs jak-2 et d'autres agents |
| WO2009039635A1 (fr) | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Procédés de modulation d'une activité médiée par la neurotrophine |
| WO2009042907A1 (fr) | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Composés d'isoindoline pour le traitement d'une amyotrophie spinale et autres utilisations |
| SI2231640T1 (sl) | 2008-01-24 | 2012-09-28 | Merck Patent Gmbh | Beta-aminokislinski derivati za zdravljenje diabetesa |
| KR101955914B1 (ko) | 2008-06-27 | 2019-03-11 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| ES2443948T3 (es) | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Compuestos de carbazol carboxamida útiles como inhibidores de quinasas |
| US8716326B2 (en) | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| WO2010151747A1 (fr) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés de pyramine ainsi que leurs procédés de fabrication et d'utilisation |
| WO2011008931A2 (fr) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés |
| CA2785499C (fr) | 2009-12-22 | 2017-05-02 | Vertex Pharmaceuticals Incorporated | Inhibiteurs d'isoindolinone de phosphatidylinositol 3-kinase |
| WO2011075784A1 (fr) | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Composés, leurs préparations et leurs utilisations |
| MX2012007692A (es) | 2009-12-31 | 2013-05-20 | Piramal Healthcare Ltd | Inhibidores del diacilglicerol acil transferasa. |
| EP2594555B1 (fr) | 2010-07-02 | 2018-03-07 | ASKA Pharmaceutical Co., Ltd. | COMPOSÉ HÉTÉROCYCLIQUE, ET INHIBITEUR DE DÉGRADATION DE p27 KIP1 |
| JP5889895B2 (ja) | 2010-07-29 | 2016-03-22 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｍｐｋ活性化複素環化合物およびその使用方法 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| HUE037423T2 (hu) | 2012-03-01 | 2018-08-28 | Array Biopharma Inc | Szerin/treonin kináz inhibitorok |
| WO2014040555A1 (fr) | 2012-09-12 | 2014-03-20 | 山东亨利医药科技有限责任公司 | Dérivé de noyau hétéroaromatique contenant de l'azote utile comme inhibiteur de la tyrosine kinase |
| WO2014055634A1 (fr) | 2012-10-02 | 2014-04-10 | Yale University | Identification de petites molécules inhibitrices d'histone déméthylase à de domaine jumonji 1a (jarid1a) et 1b (jarid1b) interactif riche en at, |
| PT2914296T (pt) | 2012-11-01 | 2018-10-30 | Infinity Pharmaceuticals Inc | Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase |
| EA201591051A1 (ru) | 2013-02-08 | 2016-06-30 | Селджен Авиломикс Рисерч, Инк. | Ингибиторы erk и варианты их применения |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| CA2922657C (fr) | 2013-08-30 | 2022-04-12 | Ptc Therapeutics, Inc. | Inhibiteurs de bmi-1 a base de pyrimidines substituees |
| WO2015048547A2 (fr) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Procédé d'utilisation de composés activant l'ampk et biomarqueurs de l'ampk |
| MY182908A (en) * | 2014-01-14 | 2021-02-05 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| US11311541B2 (en) | 2014-04-09 | 2022-04-26 | Kadmon Corporation, Llc | Treatment of GVHD |
| WO2016025649A1 (fr) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinaisons d'un inhibiteur d'erk et d'un inhibiteur de dot1l et procédés associés |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016162325A1 (fr) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-ones substitués utilisés comme inhibiteurs de kinase |
| BR112017026159A2 (pt) | 2015-06-15 | 2018-08-14 | Asana Biosciences, Llc | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer |
| CA3001799A1 (fr) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Composes benzolactames utilises en tant qu'inhibiteurs de proteine kinase |
| TN2018000119A1 (en) | 2015-11-09 | 2019-10-04 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| WO2018019204A1 (fr) | 2016-07-26 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase |
-
2017
- 2017-04-20 GB GBGB1706327.2A patent/GB201706327D0/en not_active Ceased
-
2018
- 2018-04-20 CA CA3059674A patent/CA3059674A1/fr active Pending
- 2018-04-20 BR BR112019019948A patent/BR112019019948A2/pt unknown
- 2018-04-20 IL IL269803A patent/IL269803B/en unknown
- 2018-04-20 US US16/604,002 patent/US11142518B2/en active Active
- 2018-04-20 CN CN201880024602.7A patent/CN110831939A/zh active Pending
- 2018-04-20 SG SG11201909189Q patent/SG11201909189QA/en unknown
- 2018-04-20 JP JP2019555918A patent/JP7113846B2/ja active Active
- 2018-04-20 AU AU2018255935A patent/AU2018255935B2/en active Active
- 2018-04-20 MX MX2019012471A patent/MX2019012471A/es unknown
- 2018-04-20 EP EP18722731.9A patent/EP3612524A1/fr active Pending
- 2018-04-20 MA MA052123A patent/MA52123A/fr unknown
- 2018-04-20 TW TW107113537A patent/TWI813566B/zh active
- 2018-04-20 WO PCT/IB2018/052745 patent/WO2018193410A1/fr unknown
- 2018-04-20 KR KR1020197033128A patent/KR102652193B1/ko active IP Right Grant
-
2019
- 2019-09-20 PH PH12019502154A patent/PH12019502154A1/en unknown
- 2019-10-03 SA SA519410253A patent/SA519410253B1/ar unknown
- 2019-11-12 ZA ZA2019/07484A patent/ZA201907484B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019019948A2 (pt) | 2020-04-28 |
| SG11201909189QA (en) | 2019-10-30 |
| JP2020517598A (ja) | 2020-06-18 |
| KR102652193B1 (ko) | 2024-03-29 |
| EP3612524A1 (fr) | 2020-02-26 |
| WO2018193410A1 (fr) | 2018-10-25 |
| AU2018255935A1 (en) | 2019-11-07 |
| IL269803B (en) | 2022-09-01 |
| CN110831939A (zh) | 2020-02-21 |
| US20210101889A1 (en) | 2021-04-08 |
| RU2019135029A (ru) | 2021-05-20 |
| SA519410253B1 (ar) | 2023-07-12 |
| US11142518B2 (en) | 2021-10-12 |
| ZA201907484B (en) | 2024-05-30 |
| GB201706327D0 (en) | 2017-06-07 |
| TW201842912A (zh) | 2018-12-16 |
| JP7113846B2 (ja) | 2022-08-05 |
| US20220169638A1 (en) | 2022-06-02 |
| RU2019135029A3 (fr) | 2021-07-16 |
| KR20190140957A (ko) | 2019-12-20 |
| TWI813566B (zh) | 2023-09-01 |
| MX2019012471A (es) | 2019-12-11 |
| PH12019502154A1 (en) | 2020-06-29 |
| AU2018255935B2 (en) | 2022-03-17 |
| IL269803A (en) | 2019-11-28 |
| CA3059674A1 (fr) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA46339A (fr) | Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30 | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA42032A (fr) | Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac | |
| MA53352A (fr) | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase | |
| MA40775A (fr) | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 | |
| MA52063A (fr) | Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique | |
| MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |